PT-141 (Bremelanotide): What the Research Actually Shows

PT-141, known in the research literature as bremelanotide, is a synthetic peptide that activates melanocortin receptors, a signaling system the brain uses in sexual arousal. It has more human trial evidence than almost any peptide in this catalog, so this page reports what those trials actually measured, and where the record stops.

Here is the honest version. Below is what researchers looked at, in what kind of study, and what they measured. We are telling you what researchers found, not what it does for you. One note up front: a finished, prescription version of bremelanotide is FDA-approved for one narrow medical use. That approved drug is a regulated medicine handled by a doctor, and it is a different thing from a research compound. Nothing here tells you to use either one.

What researchers have studied

Two phase 3 trials, the RECONNECT studies (Kingsberg, Obstetrics and Gynecology, 2019). A pair of identical phase 3, randomized, double-blind, placebo-controlled trials in 1,267 premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). Women got bremelanotide 1.75 mg under the skin as-needed, or placebo, for 24 weeks. Researchers reported statistically significant increases in a sexual-desire score and reductions in desire-related distress compared with placebo. Common side effects reported at 10% or higher included nausea, flushing, and headache. Human trial. PMID 31599840. https://pubmed.ncbi.nlm.nih.gov/31599840/

The long-term open-label extension (Simon, Obstetrics and Gynecology, 2019). A 52-week open-label follow-on to the trial above, meaning everyone knew they were getting the drug. Researchers reported no new safety signals over the longer window and sustained symptom scores, with nausea (about 40%) and flushing (about 21%) the most common events. Human study, open-label. PMID 31599847. https://pubmed.ncbi.nlm.nih.gov/31599847/

The RECONNECT exit study (Koochaki, Journal of Women’s Health, 2021). A patient-experience study built on surveys and interviews with women from the phase 3 trials. Researchers reported that women who received bremelanotide described more sexual desire and arousal and better-quality sexual activity with a partner. This is self-reported, qualitative data drawn from the same trial population. PMID 33538638. https://pubmed.ncbi.nlm.nih.gov/33538638/

The trial registration (ClinicalTrials.gov). The registered RECONNECT phase 3 protocol, NCT02333071, listing 723 participants across a 24-week double-blind core phase plus an optional 52-week open-label extension. Listed as completed. The record describes bremelanotide as a melanocortin agonist and a synthetic analog of the natural hormone alpha-MSH. This is a trial record, not a separate result. https://clinicaltrials.gov/study/NCT02333071

One regulatory fact. In 2019 the US FDA approved bremelanotide, sold as a finished prescription drug under the brand name Vyleesi, for one use only: HSDD in premenopausal women. That approval covers a regulated, doctor-prescribed medicine, not a research compound, and it is not a green light to self-use research material.

How it works

Most arousal drugs work on blood flow. Bremelanotide works higher up, on the brain’s melanocortin system. It is a synthetic copy of part of a natural hormone called alpha-MSH, and it switches on melanocortin receptors (chiefly MC4R) that sit in arousal-related signaling. That central action is why researchers studied it for desire rather than for mechanics.

The honest part: even with the trial data, the full chain from receptor to behavior is not completely mapped, and the human evidence sits inside one narrow group of people.

What the research does not establish

• The human evidence covers one narrow group only: premenopausal women with a specific low-desire diagnosis. It does not carry over to men, to other populations, or to general “libido” use.
• The approved product is a regulated prescription medicine handled by a doctor. A research compound is not that medicine, and approval of the drug is not permission to self-use research material.
• Trials reported side effects including nausea, flushing, and headache. Listing side effects is not a safety conclusion.
• The findings measure desire scores, distress scores, and self-report. They do not tell you what the compound would do for any one person.
• Nothing here is a safety conclusion, and this is not a claim that the compound is safe to use.
• This page is a research summary only. It does not say the compound does anything “for you,” and it is not a recommendation to use it.

The one approved use is real, and it is narrow. Everything past that edge is unsettled, whatever a seller tells you.

For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Independent identity and purity testing by Janoshik. Nothing on this page is medical advice, a health claim, or a recommendation to use.